Loading
Pairing a CD20 bispecific with a CD79b ADC lets two targeted drugs with different mechanisms replace chemotherapy in relapsed lymphoma.
This combination pairs the CD20 bispecific antibody mosunetuzumab with the CD79b antibody-drug conjugate polatuzumab vedotin in relapsed diffuse large B-cell lymphoma, replacing chemotherapy with two targeted drugs of different mechanism. The ADC debulks the tumour, lowering antigen load and with it the risk of cytokine release syndrome, and the bispecific then consolidates through T-cell killing; the toxicities of the two do not overlap. The phase 3 SUNMO trial, reported in 2025, was positive for progression-free survival against R-GemOx. The regimen is fixed-duration and can be given as an outpatient, and it sits alongside the EPCORE NHL-1 paper on epcoritamab as part of the shift to bispecific-based treatment in relapsed large B-cell lymphoma.
Shares Polatuzumab vedotin, Mosunetuzumab.
Shares SUNMO, Polatuzumab vedotin, Diffuse large B-cell lymphoma.
Shares SUNMO, Mosunetuzumab, Diffuse large B-cell lymphoma.
Shares EPCORE NHL-1: epcoritamab, a subcutaneous CD20 x CD3 bispecific, in relapsed large B-cell lymphoma including after CAR-T, Diffuse large B-cell lymphoma.